Sexual health / melanocortin

Setmelanotide

FDA-approved

Imcivree, RM-493 · MC4R agonist

MC4R agonist approved for rare genetic and hypothalamic obesity.

Half-life

~11 hours

Route

Subcutaneous daily

Evidence

FDA-approved for those rare-obesity indications; not for common obesity.

What it is

A cyclic peptide MC4R agonist (Imcivree), FDA-approved for chronic weight management in specific rare obesity disorders, with indications expanded in 2025 to acquired hypothalamic obesity.

How it works

Agonizes MC4R to restore hypothalamic leptin-melanocortin signaling, reducing hunger and increasing energy expenditure.

Studied for

POMC/PCSK1/LEPR-deficiency obesity, Bardet-Biedl syndrome, hypothalamic obesity (approved).

Regulatory status

FDA-approved (Imcivree) for specific rare-obesity indications only.

Safety

Injection-site reactions, skin hyperpigmentation, nausea, spontaneous erections, depression/suicidality monitoring; may darken moles (skin monitoring).

Reconstitution calculator →

Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.